Athersys Stock News

Many small biotech players have put the foot on the gas in 2020. With the urgent need for a COVID-19 vaccine and treatment still the number one global priority, this comes as no surprise.Athersys (ATH

Akari announced positive top line Phase 2 data. Athersys progresses with multistem COVID-19 therapy. SCWorx announces cancellation of COVID-19 test kit order.

The first patients have been enrolled in the Athersys COVID-19 induced ARDS clinical program using MultiStem cell therapy.

The first patients have been enrolled in the Athersys COVID-19 induced ARDS clinical program using MultiStem cell therapy.

Shares of Athersys (NASDAQ: ATHX) declined more than 23% last month, according to data provided by S&P; Global Market Intelligence. The stem cell stock's April decline was really just a matter of tim

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

Melbourne-based biotech company Mesoblast will enroll up to 300 COVID-19 patients for a randomized, controlled study of its stem cell therapy.

The first clinical site is now open for the MACOVIA study, a pivotal Phase 2/3 study evaluating MultiStem® cell therapy for COVID-19 induced ARDS

Athersys presentation scheduled for May 14, 2020 at 8:20 AM EDT. A live webcast will be available at https://tinyurl.com/y73g9zud

Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.